DEXCOM, INC. Net Income (Loss) Attributable to Parent, Diluted
DEXCOM, INC. (DXCM) reported Net Income (Loss) Attributable to Parent, Diluted of $250.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-07-30
- DEXCOM, INC. net income (loss) attributable to parent, diluted for the quarter ending 2026-06-30 was $250.80M, a 37.27% increase year-over-year.
- DEXCOM, INC. net income (loss) attributable to parent, diluted for the quarter ending 2026-03-31 was $201.10M, a 85.69% increase year-over-year.
- DEXCOM, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-12-31 was $269.70M, a 74.56% increase year-over-year.
- DEXCOM, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-09-30 was $286.60M, a 108.44% increase year-over-year.
- DEXCOM, INC. net income (loss) attributable to parent, diluted for fiscal 2025 was $847.30M, a 44.17% increase from fiscal 2024.
- DEXCOM, INC. net income (loss) attributable to parent, diluted for fiscal 2024 was $587.70M, a 6.06% increase from fiscal 2023.
- DEXCOM, INC. net income (loss) attributable to parent, diluted for fiscal 2023 was $554.10M, a 57.33% increase from fiscal 2022.
- DEXCOM, INC. net income (loss) attributable to parent, diluted for fiscal 2022 was $352.20M, a 54.27% increase from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $250.80M 10-Q · filed 2026-07-30 | $451.90M 10-Q · filed 2026-07-30 | $721.60M derived: sum of 3 quarters · filed 2026-07-30 | $1.01B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $201.10M 10-Q · filed 2026-04-30 | $470.80M derived: sum of 2 quarters · filed 2026-04-30 | $757.40M derived: sum of 3 quarters · filed 2026-04-30 | $940.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $269.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $556.30M derived: sum of 2 quarters · filed 2026-02-12 | $739.00M derived: sum of 3 quarters · filed 2026-07-30 | $847.30M 10-K · filed 2026-02-12 |
| 2025-09-30 | $286.60M 10-Q · filed 2025-10-30 | $469.30M derived: sum of 2 quarters · filed 2026-07-30 | $577.60M 10-Q · filed 2025-10-30 | $732.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $182.70M 10-Q · filed 2026-07-30 | $291.00M 10-Q · filed 2026-07-30 | $445.50M derived: sum of 3 quarters · filed 2026-07-30 | $583.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $108.30M 10-Q · filed 2026-04-30 | $262.80M derived: sum of 2 quarters · filed 2026-04-30 | $400.30M derived: sum of 3 quarters · filed 2026-04-30 | $546.70M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $154.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $292.00M derived: sum of 2 quarters · filed 2026-02-12 | $438.40M derived: sum of 3 quarters · filed 2026-02-12 | $587.70M 10-K · filed 2026-02-12 |
| 2024-09-30 | $137.50M 10-Q · filed 2025-10-30 | $283.90M derived: sum of 2 quarters · filed 2025-10-30 | $433.20M 10-Q · filed 2025-10-30 | $692.50M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $146.40M 10-Q · filed 2025-07-30 | $295.70M 10-Q · filed 2025-07-30 | $555.00M derived: sum of 3 quarters · filed 2026-02-12 | $678.70M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $149.30M 10-Q · filed 2025-05-01 | $408.60M derived: sum of 2 quarters · filed 2026-02-12 | $532.30M derived: sum of 3 quarters · filed 2026-02-12 | $652.00M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $259.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $383.00M derived: sum of 2 quarters · filed 2026-02-12 | $502.70M derived: sum of 3 quarters · filed 2026-02-12 | $554.10M 10-K · filed 2026-02-12 |
| 2023-09-30 | $123.70M 10-Q · filed 2024-10-24 | $243.40M derived: sum of 2 quarters · filed 2024-10-24 | $294.80M 10-Q · filed 2024-10-24 | $388.10M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $119.70M 10-Q · filed 2024-07-25 | $170.00M 10-Q · filed 2024-07-25 | $264.40M derived: sum of 3 quarters · filed 2025-02-18 | $368.40M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $50.20M 10-Q · filed 2024-04-25 | $144.70M derived: sum of 2 quarters · filed 2025-02-18 | $248.70M derived: sum of 3 quarters · filed 2025-02-18 | $301.20M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $94.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $198.50M derived: sum of 2 quarters · filed 2025-02-18 | $251.00M derived: sum of 3 quarters · filed 2025-02-18 | $352.20M 10-K · filed 2025-02-18 |
| 2022-09-30 | $104.00M 10-Q · filed 2023-10-26 | $156.50M derived: sum of 2 quarters · filed 2023-10-26 | $257.70M 10-Q · filed 2023-10-26 | $254.10M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-06-30 | $52.50M 10-Q · filed 2023-07-27 | $153.70M 10-Q · filed 2023-07-27 | $150.10M derived: sum of 3 quarters · filed 2024-02-08 | $240.20M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-03-31 | $100.10M 10-Q · filed 2023-04-27 | $97.60M derived: sum of 2 quarters · filed 2024-02-08 | $187.70M derived: sum of 3 quarters · filed 2024-02-08 | $269.00M derived: sum of 4 quarters · filed 2024-02-08 |
| 2021-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $87.60M derived: sum of 2 quarters · filed 2024-02-08 | $168.90M derived: sum of 3 quarters · filed 2024-02-08 | $228.30M 10-K · filed 2024-02-08 |
| 2021-09-30 | $90.10M 10-Q · filed 2022-10-27 | $171.40M derived: sum of 2 quarters · filed 2022-10-27 | $230.80M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $81.30M 10-Q · filed 2022-07-28 | $140.70M 10-Q · filed 2022-07-28 | ||
| 2021-03-31 | $58.20M 10-Q · filed 2022-04-28 | |||
| 2020-12-31 | $560.80M 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |